Isis Pharmaceuticals (ISIS) 57.84 $ISIS
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 18, 7:11PM CST
As the year winds down and the fund managers start selling stocks, Cramer will be watching for important earnings and economic data in a holiday-shortened week.
MU: 14.36 (+0.04), AMZN: 664.14 (-6.51), CAG: 40.59 (-0.04), NKE: 128.52 (-1.70), DIS: 107.72 (-4.29), BAC: 16.76 (-0.54), GSK: 39.43 (-0.40), K: 70.78 (-0.83), MS: 31.29 (-1.09), SHOP: 25.31 (-1.22), T: 33.60 (-0.43), AA: 9.23 (+0.08), ISIS: 57.84 (-0.36), CMI: 85.21 (-0.75), AZN: 32.80 (-0.56), RHT: 81.40 (+2.54), JUNO: 44.63 (-0.28), MSFT: 54.13 (-1.57), GIS: 56.94 (-0.29), FDC: 15.52 (-0.03), CLMT: 19.33 (+1.26), MA: 96.29 (-3.04)
Isis Pharmaceuticals
at Investor's Business Daily - Fri Dec 18, 5:47PM CST
Isis Pharmaceuticals (ISIS) said on Fri. it would change its name to avoid being confused with the radical Muslim terrorist group known as ISIS. The drugmaker said that starting Dec. 22, it will be called Ionis Pharmaceuticals. It also changed its...
ISIS: 57.84 (-0.36)
Isis Pharmaceuticals changes name to Ionis
AP - Fri Dec 18, 11:19AM CST
NEW YORK (AP) — Isis Pharmaceuticals Inc., which shares a name with the Islamic State extremist group, has changed its name to Ionis Pharmaceuticals after resisting to do so for some time.
ISIS: 57.84 (-0.36)
Isis Pharmaceuticals Changes Its Name
at The Street - Fri Dec 18, 10:30AM CST
The California-based pharmaceutical company capitulates and renames itself Ionis Pharmaceuticals.
ISIS: 57.84 (-0.36)
Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals
PR Newswire - Fri Dec 18, 8:30AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has changed its name to Ionis Pharmaceuticals, Inc. Ionis (pronounced "eye-OH-nis"
Pharmaceuticals is an original name that the Company has chosen to represent its innovative culture and heritage as both the pioneer and leader in the RNA-targeted therapeutic space for the past 26 years. Ionis is focused on bringing its late-stage Phase 3 drugs, nusinersen, volanesorsen and IONIS-TTRRx to the market and advancing its pipeline of high value drugs that have the potential to be first-in-class or best-in-class drugs to treat patients with life-threatening or serious diseases.
ISIS: 57.84 (-0.36)
Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis
PR Newswire - Thu Dec 17, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating ISIS-TTRRx in patients with wild-type transthyretin amyloidosis (wt-TTR amyloidosis, previously referred to as senile systemic amyloidosis, or SSA). The Phase 2 study will be conducted by Dr. Rodney Falk, the director of the Cardiac Amyloidosis Program and a cardiovascular medicine specialist at the Brigham and Women's Hospital in Boston.
ISIS: 57.84 (-0.36)
Will 2016 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Brian Orelli, The Motley Fool - Motley Fool - Mon Dec 14, 7:40PM CST
Next year is shaping up to be a great year for emerging biotech Alnylam Pharmaceuticals . The drugmaker expects to have 10 major clinical readouts in 2016. That's more than some one-drug-wonder biotechs have during their entire existence. The...
ISIS: 57.84 (-0.36), ALNY: 88.95 (+0.77)
7 Companies We'd Buy and Hold for the Next 20 Years
Dan Caplinger, Jason Hall, Andrés Cardenal, Steve Symington, Timothy Green, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Dec 14, 4:01PM CST
Many traders hope to get rich quick in the stock market, but over time, the best performance has come from long-term investors who choose companies that can produce solid returns year after year. The key is finding stocks that have the potential for...
AMZN: 664.14 (-6.51), ISIS: 57.84 (-0.36), IBM: 134.90 (-1.85), CMG: 541.08 (-13.81), XLK: 42.17 (-1.05), CVS: 94.86 (+0.15), MA: 96.29 (-3.04)
Isis/Biogen Initiate Amyotrophic Lateral Sclerosis Study
Zacks Equity Research - Zacks Investment Research - Mon Dec 14, 3:35PM CST
Isis Pharmaceuticals (ISIS) announced that Biogen has started a phase I/II study on ISIS-SOD1Rx for the treatment of patients with amyotrophic lateral sclerosis.
BIIB: 293.37 (-3.80), ISIS: 57.84 (-0.36), ACHN: 9.81 (+0.15), GSK: 39.43 (-0.40)
Isis Pharmaceuticals begins Phase 1/2 clinical study of ISIS-SOD1 Rx in ALS patients
M2 - Mon Dec 14, 5:10AM CST
Drug discovery company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Friday the launch of a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS) by its partner, Biogen.
ISIS: 57.84 (-0.36)
World Amyloidosis Therapeutics Pipeline Report 2015 - 13 Companies & 25 Drug Profiles
M2 - Fri Dec 11, 6:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/65kjj8/amyloidosis) has announced the addition of the "Amyloidosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Amyloidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyloidosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Arcturus Therapeutics, Inc - Bellus Health Inc. - Bsim2 - Celgene Corporation - GlaxoSmithKline Plc - Isis Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - ProteoTech, Inc. - Prothena Corporation Plc - SOM Innovation Biotech SL Drug Profiles - ALN-TTRsc02 - Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - carfilzomib - CLR-01 - eprodisate disodium - GSK-2315698 GSK-2398852 - GSK-2398852 - ISIS-TTRRx - ixazomib citrate - LUNAR-101 - LUNAR-102 - Monoclonal Antibody for Amyloidosis - Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - NEOD-001 - NPT-005 - patisiran - pomalidomide - PTI-110 - revusiran - Small Molecules for AL Amyloidosis - Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - tafamidis meglumine - tolcapone For more information visit http://www.researchandmarkets.com/research/65...myloidosis
ISIS: 57.84 (-0.36), PFE: 31.99 (-0.34), GSK: 39.43 (-0.40), PRTA: 71.03 (+3.60), CELGZ: 1.11 (-0.02)
Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
PR Newswire - Fri Dec 11, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS). ISIS-SOD1Rx is part of Isis' strategic collaboration with Biogen to discover and develop antisense drugs to treat neurological diseases. ISIS-SOD1Rx, previously referred to as ISIS-BIIB3Rx, is a Gen. 2.0+ antisense drug designed to reduce the production of superoxide dismutase 1 (SOD1). A mutation in the SOD-1 gene results in an inherited form of ALS, referred to as SOD1-ALS. SOD1-ALS is the second most common familial form of ALS, accounting for up to 20 percent of familial ALS. Familial ALS represents approximately 10 percent of all cases of ALS. Currently, treatment options for patients with ALS are extremely limited with no drugs that significantly slow disease progression.
ISIS: 57.84 (-0.36)
Positive Clinical Data Sends Isis Pharmaceuticals, Inc. Soaring in November
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 10, 7:28AM CST
Shares of Isis Pharmaceuticals , a predominantly clinical-stage antisense drug developer, soared 27% in November, based on data from S&P Capital IQ , after reporting an abundance of positive trial outcomes. The biggest boost for Isis...
BIIB: 293.37 (-3.80), ISIS: 57.84 (-0.36)
27.0% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Wed Dec 09, 9:33AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on October 26th, 2015 at $45.88. In approximately 1 month, Isis Pharmaceuticals has returned 27.02% as of today's recent price of $58.27.
ISIS: 57.84 (-0.36)
Muscular Dystrophy Global Clinical Trials - Analysis, Review, Technologies & Forecast Report H2, 2015
M2 - Tue Dec 08, 3:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/nb9xbn/muscular) has announced the addition of the "Muscular Dystrophy Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Muscular Dystrophy Global Clinical Trials Review, H2, 2015" provides an overview of Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - aTyr Pharma, Inc. - Pfizer Inc. - Bioblast Pharma Ltd. - Santhera Pharmaceuticals Holding AG - Isis Pharmaceuticals, Inc. - Genethon - AMO Pharma Limited - Alkeus Pharmaceuticals, Inc. - Alfa Wassermann S.p.A - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/nb9xbn/muscular
ISIS: 57.84 (-0.36), PFE: 31.99 (-0.34), XLRN: 44.50 (+0.59)
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, Technologies & Forecast Report H2 2015
M2 - Tue Dec 08, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/bzd833/familial_amyloid) has announced the addition of the "Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, H2 2015" report to their offering. This report provides an overview of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Familial Amyloid Polyneuropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Coverage of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) pipeline on the basis of target, MoA, route of administration and molecule type Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Devise corrective measures for pipeline projects by understanding Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alnylam Pharmaceuticals, Inc. - Arcturus Therapeutics, Inc - Bsim2 - Isis Pharmaceuticals, Inc. - Pfizer Inc. - ProteoTech, Inc. - SOM Innovation Biotech SL For more information visit http://www.researchandmarkets.com/research/bz...al_amyloid
ISIS: 57.84 (-0.36), PFE: 31.99 (-0.34)
The 3 Most Important Drugs in Isis Pharmaceuticals' Pipeline
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 07, 8:04AM CST
Image source: Isis Pharmaceuticals. When it comes to predominantly clinical-stage biotech companies, arguably no company has a deeper pipeline of developing drugs than Isis Pharmaceuticals . Isis' first approved product was Kynamro, a medicine...
BIIB: 293.37 (-3.80), ISIS: 57.84 (-0.36)
Global Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Review 2015 - 15 Companies & 27 Drug Profiles
M2 - Fri Dec 04, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7x4xtt/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Astellas Pharma Inc. - Bioblast Pharma Ltd. - Cytokinetics, Inc. - F. Hoffmann-La Roche Ltd. - Genethon - Genzyme Corporation - GMP-Orphan SAS - Isis Pharmaceuticals, Inc. - Longevity Biotech, Inc - Neurodyn Inc. - Neurotune AG - Nexgenix Pharmaceuticals, LLC - Novartis AG - Sarepta Therapeutics, Inc. - Vybion, Inc. Drug Profiles - ALB-111 - Antisense Oligonucleotide to Inhibit SMN2 gene for SMA - Antisense Oligonucleotides for Spinal Muscular Atrophy - ARM-210 - AVXS-101 - azithromycin - CK-2127107 - Gene Therapy to Activate SMN for Spinal Muscular Atrophy - Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - INT-41 - LBT-3627 - LMI-070 - ND-602 - NT-1654 - nusinersen - NXD-30001 - olesoxime - Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - PMO-25 - RG-7800 - Small Molecules for Central Nervous System Disorders - Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders - sodium phenylbutyrate - tirasemtiv For more information visit http://www.researchandmarkets.com/research/7x...l_muscular
CYTK: 10.91 (-0.58), ISIS: 57.84 (-0.36), SRPT: 37.54 (+1.71), NVS: 84.77 (-0.53)
GlobalPituitary ACTH Hypersecretion (Cushing's Disease) Therapeutics Pipeline Review, H2 2015 - 10 Companies & 18 Drug Profiles
M2 - Thu Dec 03, 7:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/2xjvzv/pituitary_acth) has announced the addition of the "Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alder Biopharmaceuticals Inc. - Corcept Therapeutics Incorporated - Cortendo AB - Cyclacel Pharmaceuticals, Inc. - ElexoPharm GmbH - Ipsen S.A. - Isis Pharmaceuticals, Inc. - Novartis AG - Orphagen Pharmaceuticals, Inc. - Pfizer Inc. Drug Profiles - ALD-1613 - AT-814 - ATR-101 - BIM-23A758 - COR-005 - CORT-125134 - ISIS-GCCRRx - ketoconazole - mifepristone - MPP-482 - osilodrostat - pasireotide LAR - Peptides to Antagonize ACTH Receptor for Cushing's Syndrome - seliciclib - Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease - Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism - Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders For more information visit http://www.researchandmarkets.com/research/2x...itary_acth
ALDR: 36.25 (+0.06), ISIS: 57.84 (-0.36), CYCC: 0.52 (+0.03), PFE: 31.99 (-0.34), CORT: 4.75 (-0.15), NVS: 84.77 (-0.53)
Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity
at The Street - Tue Dec 01, 6:57PM CST
That's especially true during December when the analysts often have nice things to say to help boost their funds going into the end of the year, Cramer says.
VRX: 108.52 (-2.86), SHAK: 39.75 (+1.21), DAL: 49.96 (-1.07), SKX: 30.00 (-0.23), PSTG: 16.81 (-0.15), INTC: 33.87 (-1.04), VTR: 53.92 (-0.89), JACK: 75.36 (+0.04), ATVI: 38.47 (-0.40), SAVE: 40.41 (-0.02), NAT: 14.32 (+0.32), GOOGL: 756.85 (-12.98), JUNO: 44.63 (-0.28), WFM: 32.75 (-0.63), BLUE: 61.45 (-0.55), MPW: 11.20 (-0.19), AMZN: 664.14 (-6.51), FRO: 3.03 (+0.10), NSC: 84.27 (-0.79), SWKS: 76.38 (-1.42), RRGB: 61.44 (-0.27), MTCH: 14.33 (+0.05), FB: 104.04 (-2.18), HABT: 23.23 (-0.28), DEPO: 19.00 (+0.15), LLY: 84.77 (-1.45), NXPI: 84.10 (-0.48), IDTI: 26.83 (-0.15), ISIS: 57.84 (-0.36), TXN: 54.94 (-1.59), MCD: 116.66 (-0.84), PX: 101.52 (-1.40), AVGO: 140.20 (-0.28)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 18, 7:11PM CST
As the year winds down and the fund managers start selling stocks, Cramer will be watching for important earnings and economic data in a holiday-shortened week.
MU: 14.36 (+0.04), AMZN: 664.14 (-6.51), CAG: 40.59 (-0.04), NKE: 128.52 (-1.70), DIS: 107.72 (-4.29), BAC: 16.76 (-0.54), GSK: 39.43 (-0.40), K: 70.78 (-0.83), MS: 31.29 (-1.09), SHOP: 25.31 (-1.22), T: 33.60 (-0.43), AA: 9.23 (+0.08), ISIS: 57.84 (-0.36), CMI: 85.21 (-0.75), AZN: 32.80 (-0.56), RHT: 81.40 (+2.54), JUNO: 44.63 (-0.28), MSFT: 54.13 (-1.57), GIS: 56.94 (-0.29), FDC: 15.52 (-0.03), CLMT: 19.33 (+1.26), MA: 96.29 (-3.04)
Isis Pharmaceuticals
at Investor's Business Daily - Fri Dec 18, 5:47PM CST
Isis Pharmaceuticals (ISIS) said on Fri. it would change its name to avoid being confused with the radical Muslim terrorist group known as ISIS. The drugmaker said that starting Dec. 22, it will be called Ionis Pharmaceuticals. It also changed its...
ISIS: 57.84 (-0.36)
Isis Pharmaceuticals changes name to Ionis
AP - Fri Dec 18, 11:19AM CST
NEW YORK (AP) — Isis Pharmaceuticals Inc., which shares a name with the Islamic State extremist group, has changed its name to Ionis Pharmaceuticals after resisting to do so for some time.
ISIS: 57.84 (-0.36)
Isis Pharmaceuticals Changes Its Name
at The Street - Fri Dec 18, 10:30AM CST
The California-based pharmaceutical company capitulates and renames itself Ionis Pharmaceuticals.
ISIS: 57.84 (-0.36)
Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals
PR Newswire - Fri Dec 18, 8:30AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has changed its name to Ionis Pharmaceuticals, Inc. Ionis (pronounced "eye-OH-nis"
Pharmaceuticals is an original name that the Company has chosen to represent its innovative culture and heritage as both the pioneer and leader in the RNA-targeted therapeutic space for the past 26 years. Ionis is focused on bringing its late-stage Phase 3 drugs, nusinersen, volanesorsen and IONIS-TTRRx to the market and advancing its pipeline of high value drugs that have the potential to be first-in-class or best-in-class drugs to treat patients with life-threatening or serious diseases. ISIS: 57.84 (-0.36)
Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis
PR Newswire - Thu Dec 17, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating ISIS-TTRRx in patients with wild-type transthyretin amyloidosis (wt-TTR amyloidosis, previously referred to as senile systemic amyloidosis, or SSA). The Phase 2 study will be conducted by Dr. Rodney Falk, the director of the Cardiac Amyloidosis Program and a cardiovascular medicine specialist at the Brigham and Women's Hospital in Boston.
ISIS: 57.84 (-0.36)
Will 2016 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Brian Orelli, The Motley Fool - Motley Fool - Mon Dec 14, 7:40PM CST
Next year is shaping up to be a great year for emerging biotech Alnylam Pharmaceuticals . The drugmaker expects to have 10 major clinical readouts in 2016. That's more than some one-drug-wonder biotechs have during their entire existence. The...
ISIS: 57.84 (-0.36), ALNY: 88.95 (+0.77)
7 Companies We'd Buy and Hold for the Next 20 Years
Dan Caplinger, Jason Hall, Andrés Cardenal, Steve Symington, Timothy Green, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Dec 14, 4:01PM CST
Many traders hope to get rich quick in the stock market, but over time, the best performance has come from long-term investors who choose companies that can produce solid returns year after year. The key is finding stocks that have the potential for...
AMZN: 664.14 (-6.51), ISIS: 57.84 (-0.36), IBM: 134.90 (-1.85), CMG: 541.08 (-13.81), XLK: 42.17 (-1.05), CVS: 94.86 (+0.15), MA: 96.29 (-3.04)
Isis/Biogen Initiate Amyotrophic Lateral Sclerosis Study
Zacks Equity Research - Zacks Investment Research - Mon Dec 14, 3:35PM CST
Isis Pharmaceuticals (ISIS) announced that Biogen has started a phase I/II study on ISIS-SOD1Rx for the treatment of patients with amyotrophic lateral sclerosis.
BIIB: 293.37 (-3.80), ISIS: 57.84 (-0.36), ACHN: 9.81 (+0.15), GSK: 39.43 (-0.40)
Isis Pharmaceuticals begins Phase 1/2 clinical study of ISIS-SOD1 Rx in ALS patients
M2 - Mon Dec 14, 5:10AM CST
Drug discovery company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Friday the launch of a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS) by its partner, Biogen.
ISIS: 57.84 (-0.36)
World Amyloidosis Therapeutics Pipeline Report 2015 - 13 Companies & 25 Drug Profiles
M2 - Fri Dec 11, 6:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/65kjj8/amyloidosis) has announced the addition of the "Amyloidosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Amyloidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyloidosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Arcturus Therapeutics, Inc - Bellus Health Inc. - Bsim2 - Celgene Corporation - GlaxoSmithKline Plc - Isis Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - ProteoTech, Inc. - Prothena Corporation Plc - SOM Innovation Biotech SL Drug Profiles - ALN-TTRsc02 - Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - carfilzomib - CLR-01 - eprodisate disodium - GSK-2315698 GSK-2398852 - GSK-2398852 - ISIS-TTRRx - ixazomib citrate - LUNAR-101 - LUNAR-102 - Monoclonal Antibody for Amyloidosis - Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - NEOD-001 - NPT-005 - patisiran - pomalidomide - PTI-110 - revusiran - Small Molecules for AL Amyloidosis - Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - tafamidis meglumine - tolcapone For more information visit http://www.researchandmarkets.com/research/65...myloidosis
ISIS: 57.84 (-0.36), PFE: 31.99 (-0.34), GSK: 39.43 (-0.40), PRTA: 71.03 (+3.60), CELGZ: 1.11 (-0.02)
Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
PR Newswire - Fri Dec 11, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS). ISIS-SOD1Rx is part of Isis' strategic collaboration with Biogen to discover and develop antisense drugs to treat neurological diseases. ISIS-SOD1Rx, previously referred to as ISIS-BIIB3Rx, is a Gen. 2.0+ antisense drug designed to reduce the production of superoxide dismutase 1 (SOD1). A mutation in the SOD-1 gene results in an inherited form of ALS, referred to as SOD1-ALS. SOD1-ALS is the second most common familial form of ALS, accounting for up to 20 percent of familial ALS. Familial ALS represents approximately 10 percent of all cases of ALS. Currently, treatment options for patients with ALS are extremely limited with no drugs that significantly slow disease progression.
ISIS: 57.84 (-0.36)
Positive Clinical Data Sends Isis Pharmaceuticals, Inc. Soaring in November
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 10, 7:28AM CST
Shares of Isis Pharmaceuticals , a predominantly clinical-stage antisense drug developer, soared 27% in November, based on data from S&P Capital IQ , after reporting an abundance of positive trial outcomes. The biggest boost for Isis...
BIIB: 293.37 (-3.80), ISIS: 57.84 (-0.36)
27.0% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Wed Dec 09, 9:33AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on October 26th, 2015 at $45.88. In approximately 1 month, Isis Pharmaceuticals has returned 27.02% as of today's recent price of $58.27.
ISIS: 57.84 (-0.36)
Muscular Dystrophy Global Clinical Trials - Analysis, Review, Technologies & Forecast Report H2, 2015
M2 - Tue Dec 08, 3:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/nb9xbn/muscular) has announced the addition of the "Muscular Dystrophy Global Clinical Trials Review, H2, 2015" report to their offering. Our clinical trial report, Muscular Dystrophy Global Clinical Trials Review, H2, 2015" provides an overview of Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - aTyr Pharma, Inc. - Pfizer Inc. - Bioblast Pharma Ltd. - Santhera Pharmaceuticals Holding AG - Isis Pharmaceuticals, Inc. - Genethon - AMO Pharma Limited - Alkeus Pharmaceuticals, Inc. - Alfa Wassermann S.p.A - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/nb9xbn/muscular
ISIS: 57.84 (-0.36), PFE: 31.99 (-0.34), XLRN: 44.50 (+0.59)
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, Technologies & Forecast Report H2 2015
M2 - Tue Dec 08, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/bzd833/familial_amyloid) has announced the addition of the "Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, H2 2015" report to their offering. This report provides an overview of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Familial Amyloid Polyneuropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Coverage of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) pipeline on the basis of target, MoA, route of administration and molecule type Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Devise corrective measures for pipeline projects by understanding Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alnylam Pharmaceuticals, Inc. - Arcturus Therapeutics, Inc - Bsim2 - Isis Pharmaceuticals, Inc. - Pfizer Inc. - ProteoTech, Inc. - SOM Innovation Biotech SL For more information visit http://www.researchandmarkets.com/research/bz...al_amyloid
ISIS: 57.84 (-0.36), PFE: 31.99 (-0.34)
The 3 Most Important Drugs in Isis Pharmaceuticals' Pipeline
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 07, 8:04AM CST
Image source: Isis Pharmaceuticals. When it comes to predominantly clinical-stage biotech companies, arguably no company has a deeper pipeline of developing drugs than Isis Pharmaceuticals . Isis' first approved product was Kynamro, a medicine...
BIIB: 293.37 (-3.80), ISIS: 57.84 (-0.36)
Global Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Review 2015 - 15 Companies & 27 Drug Profiles
M2 - Fri Dec 04, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7x4xtt/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Astellas Pharma Inc. - Bioblast Pharma Ltd. - Cytokinetics, Inc. - F. Hoffmann-La Roche Ltd. - Genethon - Genzyme Corporation - GMP-Orphan SAS - Isis Pharmaceuticals, Inc. - Longevity Biotech, Inc - Neurodyn Inc. - Neurotune AG - Nexgenix Pharmaceuticals, LLC - Novartis AG - Sarepta Therapeutics, Inc. - Vybion, Inc. Drug Profiles - ALB-111 - Antisense Oligonucleotide to Inhibit SMN2 gene for SMA - Antisense Oligonucleotides for Spinal Muscular Atrophy - ARM-210 - AVXS-101 - azithromycin - CK-2127107 - Gene Therapy to Activate SMN for Spinal Muscular Atrophy - Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - INT-41 - LBT-3627 - LMI-070 - ND-602 - NT-1654 - nusinersen - NXD-30001 - olesoxime - Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - PMO-25 - RG-7800 - Small Molecules for Central Nervous System Disorders - Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders - sodium phenylbutyrate - tirasemtiv For more information visit http://www.researchandmarkets.com/research/7x...l_muscular
CYTK: 10.91 (-0.58), ISIS: 57.84 (-0.36), SRPT: 37.54 (+1.71), NVS: 84.77 (-0.53)
GlobalPituitary ACTH Hypersecretion (Cushing's Disease) Therapeutics Pipeline Review, H2 2015 - 10 Companies & 18 Drug Profiles
M2 - Thu Dec 03, 7:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/2xjvzv/pituitary_acth) has announced the addition of the "Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alder Biopharmaceuticals Inc. - Corcept Therapeutics Incorporated - Cortendo AB - Cyclacel Pharmaceuticals, Inc. - ElexoPharm GmbH - Ipsen S.A. - Isis Pharmaceuticals, Inc. - Novartis AG - Orphagen Pharmaceuticals, Inc. - Pfizer Inc. Drug Profiles - ALD-1613 - AT-814 - ATR-101 - BIM-23A758 - COR-005 - CORT-125134 - ISIS-GCCRRx - ketoconazole - mifepristone - MPP-482 - osilodrostat - pasireotide LAR - Peptides to Antagonize ACTH Receptor for Cushing's Syndrome - seliciclib - Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease - Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism - Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders For more information visit http://www.researchandmarkets.com/research/2x...itary_acth
ALDR: 36.25 (+0.06), ISIS: 57.84 (-0.36), CYCC: 0.52 (+0.03), PFE: 31.99 (-0.34), CORT: 4.75 (-0.15), NVS: 84.77 (-0.53)
Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity
at The Street - Tue Dec 01, 6:57PM CST
That's especially true during December when the analysts often have nice things to say to help boost their funds going into the end of the year, Cramer says.
VRX: 108.52 (-2.86), SHAK: 39.75 (+1.21), DAL: 49.96 (-1.07), SKX: 30.00 (-0.23), PSTG: 16.81 (-0.15), INTC: 33.87 (-1.04), VTR: 53.92 (-0.89), JACK: 75.36 (+0.04), ATVI: 38.47 (-0.40), SAVE: 40.41 (-0.02), NAT: 14.32 (+0.32), GOOGL: 756.85 (-12.98), JUNO: 44.63 (-0.28), WFM: 32.75 (-0.63), BLUE: 61.45 (-0.55), MPW: 11.20 (-0.19), AMZN: 664.14 (-6.51), FRO: 3.03 (+0.10), NSC: 84.27 (-0.79), SWKS: 76.38 (-1.42), RRGB: 61.44 (-0.27), MTCH: 14.33 (+0.05), FB: 104.04 (-2.18), HABT: 23.23 (-0.28), DEPO: 19.00 (+0.15), LLY: 84.77 (-1.45), NXPI: 84.10 (-0.48), IDTI: 26.83 (-0.15), ISIS: 57.84 (-0.36), TXN: 54.94 (-1.59), MCD: 116.66 (-0.84), PX: 101.52 (-1.40), AVGO: 140.20 (-0.28)
